# Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

> **NCT01822613** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** LJM716
- **DRUG:** BYL719
- **DRUG:** Paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT01822613
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-26
- **Primary completion:** 2016-06-03
- **Final completion:** 2016-06-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01822613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01822613, "Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01822613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*